Press Releases

March 18, 2019
Cold Genesys Closes $22 Million Series C Financing

November 28, 2018
Cold Genesys Announces Clinical Trial Collaboration to Evaluate the Combination of CG0070 and KEYTRUDA® (pembrolizumab) in Bladder Cancer

October 22, 2018
Cold Genesys Announces New Leadership Appointments

May 15, 2017
Cold Genesys Announces Clinical Results at American Urological Association (AUA) Annual Meeting 2017

April 25, 2017
Cold Genesys Announces Acceptance of Late Breaking Abstract at American Urological Association (AUA) Annual Meeting 2017​

October 19, 2015
Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer​

August 5, 2015
Cold Genesys Secures Series B Investment for Pivotal and Combo Immunotherapy Trials - Ally Bridge and WI Harper Co-lead US$10 million Series B Financing

July 30, 2014
Cold Genesys Raises $13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer


November 28, 2018
Presenting at Society of Urologic Oncology (SUO) Meeting
Phoenix, AZ
- November 28-30, 2018

June 1, 2018
Presenting at American Society of Clinical Oncology (ASCO) Meeting
Chicago, IL - June 1-5, 2018

May 18, 2018
Presenting at American Urological Association (AUA) Meeting
San Francisco, CA - May 18-21, 2018

February 29, 2016
BioCentury, Infectious Enthusiasm (pdf)

October 20, 2015
Presenting at 14th Annual BIO Investor Forum
San Francisco, CA - October 20-21, 2015

September 9, 2015
2015 BIO Investor Forum Buzz of BIO Winners Announced - Recognizing Highly Innovative Companies in the Biotech Sector